INSIGHT: Managing Risks and Uncertainty in Licensing Early-Stage Therapies

INSIGHT: Managing Risks and Uncertainty in Licensing Early-Stage Therapies

Sean Sheridan , Zlatina Dobreva
Life Sciences Strategy

Sean Sheridan and Zlatina Dobreva discuss the importance of licensing intellectual property in the life sciences industry in the successful commercialization of early-stage therapeutics. Different licensing structures reflect the need for licensors and licensees to consider the range of paths for early-stage biotechnology development and then take all available and mutually agreeable steps to protect their interests. Read the full piece below.

Bloomberg Law